Get the Stockscreener App
0.4031
0.47%
0.0019
Traws Pharma Inc stock is traded at $0.4031, with a volume of 36,127.
It is up +0.47% in the last 24 hours and down -23.80% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
See More
Previous Close:
$0.4012
Open:
$0.4
24h Volume:
36,127
Relative Volume:
0.19
Market Cap:
$6.19M
Revenue:
$2.73M
Net Income/Loss:
$-19.43M
P/E Ratio:
-0.1773
EPS:
-2.2739
Net Cash Flow:
$-17.91M
1W Performance:
-16.07%
1M Performance:
-23.80%
6M Performance:
-67.23%
1Y Performance:
-85.76%
1-Day Range:
$0.391
$0.4144
1-Week Range:
$0.391
$0.4731
52-Week Range:
$0.391
$3.23
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.4031 | 6.19M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-26 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionATR Stop - vinanet.vn
Traws (TRAW) Shares: Ends Higher by 1.92% at $0.53 in the Current Update; Market Levels: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionHigh Yield Stocks - siam.in
H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0
TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com UK
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
Traws Pharma (NasdaqCM:TRAW) Stock Forecast & Analyst Predictions - Simply Wall Street
Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com Australia
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com UK
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus
Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan
Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart
Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade
Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks
Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade
Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traws Pharma, Inc. Q2 2026: Revenue $0 EPS $(0.16) — 10-Q Summary - TradingView
TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView
Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewswire
Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan
Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan
Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan
Traws Pharma Q1 2026 Earnings: Net Loss Narrows Sharply, EPS Beats Consensus by 29.78%Analyst Earnings Estimate - dars.gov.et
Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Traws Pharma Inc (TRAW) Stock News Today - TradingKey
Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
TRAW Q1 2026 Earnings: Loss Narrows 29.8% Versus Estimates as Pre-Revenue Biotech Holds CourseEPS Consistency Score - vinanet.vn
TRAW Q2'26 Earnings: EPS estimate is (0.34) USD - TradingView
TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch - tipranks.com
Traws Pharma, Inc. Files Form 8-K: Company Details, NASDAQ Listing, and Compliance Information (July 2026) - Minichart
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW - TradingView
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentROIC Trend Report - dars.gov.et
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Traws Pharma Received Notice of Noncompliance - TradingView
Traws Pharma (TRAW) Edges Higher: Micro-Cap Biotech Defends $0.43 SupportHead and Shoulders - vinanet.vn
TRAW Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Traws Pharma Inc (TRAW) Balance Sheet - TradingKey
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):